Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 14/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27616956 | 0.98 | HPGDS (0.56) | HPGDSPDGFRBPDGFRAEGFRMAOB | |
| SCHEMBL4732216 | 0.87 | ALDH1A1 (0.57) | HPGDSPDGFRBPDGFRAEGFRALDH1A1 | |
| Ethane SCHEMBL27947699 | 0.86 | ALDH1A1 (0.56) | HPGDSPDGFRBPDGFRAEGFRALDH1A1 | |
| SCHEMBL11971504 | 0.86 | MAOB (0.47) | HPGDSPDGFRBPDGFRAMAOBALDH1A1 | |
| Butane SCHEMBL27931334 | 0.83 | ALDH1A1 (0.54) | HPGDSPDGFRBPDGFRAEGFRALDH1A1 | |
| SCHEMBL28263656 | 0.83 | PDGFRB (0.39) | HPGDSPDGFRBPDGFRAEGFRMAOB | |
| SCHEMBL2444131 | 0.80 | THRA (0.43) | ALDH1A1 | |
| SCHEMBL9797715 | 0.79 | PDGFRB (0.42) | PDGFRBPDGFRAEGFRALDH1A1CYP2A6 | |
| SCHEMBL28808959 | 0.79 | HPGDS (0.65) | HPGDSPDGFRBPDGFRAEGFRALDH1A1 | |
| SCHEMBL554880 | 0.78 | ALDH1A1 (0.50) | PDGFRBPDGFRAMAOBALDH1A1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902710-B2 | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | EXONHIT THERAPEUTICS, SA (FR) | 2018-02-27 | — | — | US | disclosed |
| US-9670181-B2 | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | ALLERGAN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670181-B2 | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | ALLERGAN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670181-B2 | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | ALLERGAN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160264549-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | EXONHIT THERAPEUTICS, SA (FR) | 2016-09-15 | — | — | US | disclosed |
| EP-2675791-B1 | SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE10A) | ALLERGAN INC (US) | 2016-02-17 | — | — | EP | disclosed |
| EP-2675791-B1 | SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE10A) | ALLERGAN INC (US) | 2016-02-17 | — | — | EP | disclosed |
| US-9200016-B2 | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | ALLERGAN, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150158895-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | ALLERGAN, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20140309253-A1 | SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | ALLERGAN, INC. | 2014-10-16 | — | — | US | disclosed |
| US-7332511-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7148221-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-7144888-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1717220-A2 | Vanilloid receptor ligands and their use in treatments | Amgen, Inc (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-1688408-A2 | Vanilloid receptor ligands and their use in treatments | Amgen, Inc (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1546116-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004014871-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309253-A1 | SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | PDE10A, PDE6A, PDE9A | HPGDS 1708/4885PDGFRB 1320/4885PDGFRA 1047/4885 |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | HPGDS 206/4885PDGFRB 282/4885PDGFRA 332/4885 |
| US-20160264549-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | PDE9A, PDE10A, PDE6A | HPGDS 2094/4885PDGFRB 1521/4885PDGFRA 1313/4885 |
| US-20150158895-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | PDE9A, PDE10A, PDE6A | HPGDS 2094/4885PDGFRB 1521/4885PDGFRA 1313/4885 |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | HPGDS 206/4885PDGFRB 282/4885PDGFRA 332/4885 |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | HPGDS 251/4885PDGFRB 304/4885PDGFRA 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.